Evidence map›Paper›PMID 35458639›Full record

ArticleMolecules (Basel, Switzerland)2022

Self-Assembled Alkylated Polyamine Analogs as Supramolecular Anticancer Agents.

Diptesh Sil, Sudipta Panja, Chinmay M Jogdeo, Raj Kumar, Ao Yu, Cassandra E Holbert, Ling Ding, Jackson R Foley, Tracy Murray Stewart, Robert A Casero and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Diptesh SilDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Sudipta PanjaDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Chinmay M JogdeoDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-0018-1684
Raj KumarDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-4019-9942
Ao YuDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Cassandra E HolbertSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Ling DingDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Jackson R FoleySidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Tracy Murray StewartSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0001-8679-6414
Robert A CaseroSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
David OupickýDepartment of Pharmaceutical Sciences, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-4710-861X
University of Nebraska Medical Center · USJohns Hopkins University · US

Funding

TRAINING IN AREAS FUNDAMENTAL TO CANCER RESEARCHT32CA009110 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J., WEERARATNA, ASHANI T · 1985 to 2025
$13.1M
Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention targetR01CA204345 · NCI · JOHNS HOPKINS UNIVERSITY · PI CASERO, ROBERT A., WOSTER, PATRICK M · 2016 to 2020
$3.4M
Self-immolative prodrug/miRNA nanoparticle combinations for cancer treatmentR01CA235863 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CASERO, ROBERT A., OUPICKY, DAVID · 2019 to 2023
$2.3M
NCI NIH HHS R01 CA204345NCI NIH HHS R01 CA235863NCI NIH HHS T32 CA009110NIH HHS CA204345NIH HHS R01 CA235863
6 · The paper itself

Abstract

Conformationally restrained polyamine analog PG11047 is a well-known drug candidate that modulates polyamine metabolism and inhibits cancer cell growth in a broad spectrum of cancers. Here, we report a structure-activity relationship study of the PG11047 analogs (HPGs) containing alkyl chains of varying length, while keeping the unsaturated spermine backbone unchanged. Synthesis of higher symmetrical homologues was achieved through a synthetic route with fewer steps than the previous route to PG11047. The amphiphilic HPG analogs underwent self-assembly and formed spherically shaped nanoparticles whose size increased with the hydrophobic alkyl group's increasing chain length. Assessment of the in vitro anticancer activity showed more than an eight-fold increase in the cancer cell inhibition activity of the analogs with longer alkyl chains compared to PG11047 in human colon cancer cell line HCT116, and a more than ten-fold increase in human lung cancer cell line A549. Evaluation of the inhibition of spermine oxidase (SMOX) showed no activity for PG11047, but activity was observed for its higher symmetrical homologues. Comparison with a reference SMOX inhibitor MDL72527 showed nine-fold better activity for the best performing HPG analog.

Indexed as

Antineoplastic AgentsLung NeoplasmsNanoparticlesCell Line, TumorHumansPolyaminesSpermineAntineoplastic AgentsPolyaminesSperminecancer therapyPG11047polyamine analogsself-assemblyspermine oxidase

Identifiers

PMID35458639
PMCPMC9032695
OpenAlexW4223638393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.